Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation and Steatosis

Current Pathobiology Reports

Volumn 1, Issue 3, 2013, Pages 147-157

  Massart, Julie ^b   Begriche, Karima ^a   Buron, Nelly ^c   Porceddu, Mathieu ^c   Borgne Sanchez, Annie ^c   Fromenty, Bernard ^a  

^a INSERM   (France)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Drug; Fatty acid oxidation; Fatty liver; Mitochondria; Respiratory chain; Steatosis

Indexed keywords

EID: 84888436247     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-013-0022-y     Document Type: Article

References (100)

1. •• Biour M, Ben Salem C, Chazouillères O, et al (2004) Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs. Gastroenterol Clin Biol 28:720–759. This article provides an essential database concerning DILI for more than a thousand pharmaceuticals. Importantly, this French database is now available on line (http://server1.dicofm.com/hepatox/index.php) and is regularly updated. Another important database regarding DILI is the FDA’s Liver Toxicity Knowledge Base (LTKB) (http://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase).
2. Ramachandran R, Kakar S (2009) Histological patterns in drug-induced liver disease. J Clin Pathol 62:481–492
3. Fromenty B, Pessayre D (1995) Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67:101–154
4. Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22:335–353
5. Begriche K, Massart J, Robin MA et al (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 54:773–794
6. Pessayre D, Mansouri A, Berson A et al (2010) Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 196:311–365
7. Pessayre D, Fromenty B, Berson A et al (2012) Central role of mitochondria in drug-induced liver injury. Drug Metab Rev 44:34–87
8. Wallace DC, Fan W, Procaccio V (2010) Mitochondrial energetics and therapeutics. Annu Rev Pathol 5:297–348
9. Begriche K, Massart J, Robin MA et al (2013) Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology (in press)
10. Shekhawat PS, Matern D, Strauss AW (2005) Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res 57:78R–86R
11. Fromenty B, Fisch C, Berson A et al (1990) Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and II. J Pharmacol Exp Ther 255:1377–1384
12. •• Porceddu M, Buron N, Roussel C, et al (2012) Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci. 129:332–345. This article reports the effects of more than a hundred drugs on different mitochondrial parameters including oxygen consumption, membrane potential, swelling and cytochrome c release. The data revealed a highly significant relationship between mitochondrial toxicity and the occurrence of drug-induced liver injury in human.
13. Fromenty B, Letteron P, Fisch C et al (1993) Evaluation of human blood lymphocytes as a model to study the effects of drugs on human mitochondria. Effects of low concentrations of amiodarone on fatty acid oxidation, ATP levels and cell survival. Biochem Pharmacol 46:421–432
14. Ducluzeau PH, Lachaux A, Bouvier R et al (2002) Progressive reversion of clinical and molecular phenotype in a child with liver mitochondrial DNA depletion. J Hepatol 36:698–703
15. Igoudjil A, Begriche K, Pessayre D et al (2006) Mitochondrial, metabolic and genotoxic effects of antiretroviral nucleoside reverse-transcriptase inhibitors. Curr Med Chem Anti Infect Agents 5:273–292
16. Velsor LW, Kovacevic M, Goldstein M et al (2004) Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol 199:10–19
17. Golubitzky A, Dan P, Weissman S et al (2011) Screening for active small molecules in mitochondrial complex I deficient patient’s fibroblasts, reveals AICAR as the most beneficial compound. PLoS ONE 6:e26883
18. Kazak L, Reyes A, Holt IJ (2012) Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol 13:659–671
19. Wolfrum C, Stoffel M (2006) Coactivation of Foxa2 through PGC-1β promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 3:99–110
20. Knapp AC, Todesco L, Torok M et al (2008) Effect of carnitine deprivation on carnitine homeostasis and energy metabolism in mice with systemic carnitine deficiency. Ann Nutr Metab 52:136–144
21. Fromenty B, Fisch C, Labbe G et al (1990) Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 255:1371–1376
22. Berson A, Schmets L, Fisch C et al (1994) Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen. J Pharmacol Exp Ther 270:167–176
23. Dykens JA, Jamieson J, Marroquin L et al (2008) Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 233:203–210
24. Fromenty B, Fréneaux E, Labbe G et al (1989) Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol 38:3743–3751
25. Fréneaux E, Fromenty B, Berson A et al (1990) Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial beta-oxidation of fatty acids. J Pharmacol Exp Ther 255:529–535
26. Deschamps D, DeBeco V, Fisch C et al (1994) Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 19:948–961
27. Baldwin GS, Murphy VJ, Yang Z et al (1998) Binding of nonsteroidal antiinflammatory drugs to the α-subunit of the trifunctional protein of long chain fatty acid oxidation. J Pharmacol Exp Ther 286:1110–1114
28. Larosche I, Lettéron P, Fromenty B et al (2007) Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 321:526–535
29. • Aires CC, Ijlst L, Stet F, Prip-Buus C, et al (2010) Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol. 79:792–799. This article showed that valproyl-CoA is inhibiting CPT1, a key enzyme involved in the mitochondrial β-oxidation of LCFAs. Many other investigations from this group deciphered the mitochondrial toxicity of this antiepileptic drug (see for instance references 30 and 40).
30. Silva MF, Ruiter JP, Ijlst L et al (2001) Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. Chem Biol Interact 137:203–212
31. Chen C, Krausz KW, Shah YM et al (2009) Serum metabolomics reveals irreversible inhibition of fatty acid β-oxidation through the suppression of PPARα activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol 22:699–707
32. Burcham PC, Harman AW (1991) Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem 266:5049–5054
33. Knockaert L, Descatoire V, Vadrot N et al (2011) Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen. Toxicol In Vitro 25:475–484
34. Huang Q, Jin X, Gaillard ET et al (2004) Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutat Res 549:147–167
35. Yohe HC, O’Hara KA, Hunt JA et al (2006) Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity. Am J Physiol Gastrointest Liver Physiol 290:G1269–G1279
36. Aubert J, Begriche K, Delannoy M et al (2012) Differences in early acetaminophen hepatotoxicity between obese ob/ob and db/db mice. J Pharmacol Exp Ther 342:676–687
37. Kennedy JA, Unger SA, Horowitz JD (1996) Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52:273–280
38. Fulgencio JP, Kohl C, Girard J et al (1996) Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45:1556–1562
39. Deschamps D, Fisch C, Fromenty B et al (1991) Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye’s syndrome. J Pharmacol Exp Ther 259:894–904
40. Luís PB, Ruiter JP, Ofman R et al (2011) Valproic acid utilizes the isoleucine breakdown pathway for its complete β-oxidation. Biochem Pharmacol 82:1740–1746
41. Berson A, Fau D, Fornacciari R et al (2001) Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 34:261–269
42. Fréneaux E, Labbe G, Letteron P et al (1988) Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 8:1056–1062
43. Labbe G, Fromenty B, Freneaux E et al (1991) Effects of various tetracycline derivatives on in vitro and in vivo beta-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice. Biochem Pharmacol 41:638–641
44. Yu HY, Wang BL, Zhao J et al (2009) Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Toxicology 261:112–118
45. Cuenca-Lopez MD, Karachitos A, Massarotto L et al (2012) Minocycline exerts uncoupling and inhibiting effects on mitochondrial respiration through adenine nucleotide translocase inhibition. Pharmacol Res 65:120–128
46. Abdel-Razaq W, Kendall DA, Bates TE (2011) The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem Res 36:327–338
47. Hroudová J, Fišar Z (2012) In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicol Lett 213:345–352
48. Sandoval-Acuña C, Lopez-Alarcón C, Aliaga ME et al (2012) Inhibition of mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection by quercetin via a coenzyme Q-like action. Chem Biol Interact 199:18–28
49. 2+ on oxidative phosphorylation in liver, brain, and heart mitochondria using state 3 oxidation rate assays. Toxicol Appl Pharmacol 249:65–75
50. Lewis W, Levine ES, Griniuviene B et al (1996) Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 93:3592–3597
51. Walker UA, Venhoff N (2005) Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 10(Suppl 2):M117–M123
52. Mansouri A, Haouzi D, Descatoire V et al (2003) Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver. Hepatology 38:715–725
53. Cover C, Mansouri A, Knight TR et al (2005) Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. J Pharmacol Exp Ther 315:879–887
54. Rachek LI, Yuzefovych LV, Ledoux SP et al (2009) Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol 240:348–354
55. Demeilliers C, Maisonneuve C, Grodet A et al (2002) Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 123:1278–1290
56. Wang W, Lin R, Zhang J et al (2012) Involvement of fatty acid metabolism in the hepatotoxicity induced by divalproex sodium. Hum Exp Toxicol 31:1092–1101
57. McCarthy TC, Pollak PT, Hanniman EA et al (2004) Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-α target gene activation. J Pharmacol Exp Ther 311:864–873
58. van der Leij FR, Bloks VW, Grefhorst A et al (2007) Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. Genomics 90:680–689
59. Fromenty B (2013) Drug-induced liver injury in obesity. J Hepatol 58:824–826
60. Lettéron P, Sutton A, Mansouri A et al (2003) Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38:133–140
61. • Anthérieu S, Rogue A, Fromenty B, et al (2011) Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 53:1895–1905. This article was the first report demonstrating that amiodarone and tetracycline was able to induce vesicular steatosis in the well-differentiated human hepatoma HepaRG cells. This study confirmed that both drugs can inhibit mitochondrial β-oxidation as previously described [21, 37, 42-44, 74–76], but also revealed that amiodarone could also increase de novo lipogenesis.
62. Genève J, Hayat-Bonan B, Labbe G et al (1987) Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 242:1133–1137
63. Bickel PE, Tansey JT, Welte MA (2009) PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochem Biophys Acta 1791:419–440
64. Scaini G, Simon KR, Tonin AM et al (2012) Toxicity of octanoate and decanoate in rat peripheral tissues: evidence of bioenergetic dysfunction and oxidative damage induction in liver and skeletal muscle. Mol Cell Biochem 361:329–335
65. Kleiner DE, Gaffey MJ, Sallie R et al (1997) Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 10:192–199
66. Caldwell SH, Hespenheide EE, von Borstel RW (2001) Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 46:376–378
67. Fukano M, Amano S, Sato J et al (2000) Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum Pathol 31:250–253
68. Kohlroser J, Mathai J, Reichheld J et al (2000) Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95:272–276
69. Derks TG, van Dijk TH, Grefhorst A et al (2008) Inhibition of mitochondrial fatty acid oxidation in vivo only slightly suppresses gluconeogenesis but enhances clearance of glucose in mice. Hepatology 47:1032–1042
70. Le Dinh T, Freneaux E, Labbe G et al (1988) Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 247:745–750
71. • Shi X, Yao D, Gosnell BA, et al (2012) Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity. J Lipid Res. 53:2318–2330. This study epitomizes the fact that non-pharmaceutical compounds are able to inhibit mitochondrial β-oxidation and cause microvesicular steatosis. In this study, cocaine-induced inhibition of hepatic β-oxidation was associated with the accumulation of palmitoyl-carnitine in serum and liver. Interestingly, accretion of acyl-carnitine derivatives can be also observed with valproic acid.
72. Fu Q, Huang X, Shu B et al (2011) Inhibition of mitochondrial respiratory chain is involved in triptolide-induced liver injury. Fitoterapia 82:1241–1248
73. Wan HT, Zhao YG, Wei X et al (2012) PFOS-induced hepatic steatosis, the mechanistic actions on β-oxidation and lipid transport. Biochim Biophys Acta 1820:1092–1101
74. Spaniol M, Bracher R, Ha HR et al (2001) Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol 35:628–636
75. Kaufmann P, Török M, Hänni A et al (2005) Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41:925–935
76. • Felser A, Blum K, Lindinger PW, et al (2013) Mechanisms of hepatocellular toxicity associated with dronedarone. A comparison to amiodarone. Toxicol Sci. 131:480–490. This article showed for the first time that the new antiarrhythmic drug dronedarone is able to impair mitochondrial function in a similar way that amiodarone, its structural analogue. Moreover, this article and others (see for instance [74] and [75]) confirmed our original data published in 1990 showing that amiodarone can have a dual effect on OXPHOS (i.e. uncoupling and inhibition) and inhibit mitochondrial fatty acid β-oxidation [11, 21].
77. Surendradoss J, Chang TK, Abbott FS (2012) Assessment of the role of in situ generated (E)-2,4-diene-valproic acid in the toxicity of valproic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes. Toxicol Appl Pharmacol 264:413–422
78. Walker UA, Bäuerle J, Laguno M et al (2004) Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 39:311–317
79. Boubaker K, Flepp M, Sudre P et al (2001) Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 33:1931–1937
80. Finsterer J, Segall L (2010) Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 33:138–151
81. Bailey CM, Kasiviswanathan R, Copeland WC et al (2009) R964C mutation of DNA polymerase γ imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity. Antimicrob Agents Chemother 53:2610–2612
82. • Stewart JD, Horvath R, Baruffini E, et al (2010) Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology. 52:1791–1796. This article showed for the first time that a particular genetic variation in the POLG gene was strongly associated with valproate-induced liver toxicity. This gene is encoding the DNA polymerase γ, which is the only DNA polymerase involved in mtDNA replication. However, it is still unclear how mutations in the POLG gene could favor VPA-induced liver injury, contrary to antiretroviral nucleoside analogue-induced toxicity [81].
83. Degoul F, Sutton A, Mansouri A et al (2001) Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 120:1468–1474
84. +/− mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today 13:982–988
85. Begriche K, Lettéron P, Abbey-Toby A et al (2008) Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab 294:E939–E951
86. Farrell GC (2002) Drugs and steatohepatitis. Semin Liver Dis 22:185–194
87. Grismer LE, Gill SA, Harris MD (2001) Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J Clin Rheumatol 7:224–227
88. Zorzi D, Laurent A, Pawlik TM et al (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94:274–286
89. Berson A, De Beco V, Lettéron P et al (1998) Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114:764–774
90. Mitchell C, Mahrouf-Yorgov M, Mayeuf A et al (2011) Overexpression of Bcl-2 in hepatocytes protects against injury but does not attenuate fibrosis in a mouse model of chronic cholestatic liver disease. Lab Invest 91:273–282
91. Brady LJ, Brady PS, Romsos DR et al (1985) Elevated hepatic mitochondrial and peroxisomal oxidative capacities in fed and starved adult obese (ob/ob) mice. Biochem J 231:439–444
92. Takamura T, Shimizu A, Komura T et al (2007) Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. Intern Med 46:579–581
93. Igoudjil A, Massart J, Begriche K et al (2008) High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol In Vitro 22:887–898
94. Martins-Maciel ER, Campos LB, Salgueiro-Pagadigorria CL et al (2013) Raloxifene affects fatty acid oxidation in livers from ovariectomized rats by acting as a pro-oxidant agent. Toxicol Lett 217:82–89
95. Nazarewicz RR, Zenebe WJ, Parihar A et al (2007) Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 67:1282–1290
96. Singh K, Malviya A, Bhori M et al (2012) An in vitro study of the ameliorative role of α-tocopherol on methotrexate-induced oxidative stress in rat heart mitochondria. J Basic Clin Physiol Pharmacol 23:163–168
97. Cole LK, Jacobs RL, Vance DE (2010) Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 52:1258–1265
98. ® . This methodology can allow the high-throughput assessment of drug-induced alteration of mitochondrial function such as MRC activity and mtFAO ([12] and Table 2).
99. Robinson SM, Wilson CH, Burt AD et al (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19:4287–4299
100. Wang Y, Lin Z, Liu Z et al (2013) A unifying ontology to integrate histological and clinical observations for drug-induced liver injury. Am J Pathol 182:1180–1187